Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 10180Neoplasms 7807Carcinoma, Non-Small-Cell Lung 5756Prostatic Neoplasms 5024Colorectal Neoplasms 4603Lung Neoplasms 3723Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3082Multiple Myeloma 3081Pancreatic Neoplasms 2843Melanoma 2651Ovarian Neoplasms 2573Lymphoma 2570Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Recurrence 2229Head and Neck Neoplasms 2102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia 2013Brain Neoplasms 1902Glioblastoma 1795Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1719Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Malignant Carcinoid Syndrome × Clear all
NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡